II. Indication
- First line agent for Open Angle Glaucoma
III. Contraindications
- Active Uveitis
IV. Mechanism
- Prostaglandin analogs that increase uveoscleral aqueous outflow (lowers IOP 25 to 35%)
V. Medications (Teal Caps)
- Latanoprost (Xalatan) 0.005% one drop daily
- Bimatoprost (Lumigan) 0.03% one drop daily
- Travoprost (Travatan) 0.004% one drop daily
- Unoprostone (Rescula) 0.15% one drop daily
- Tafluprost (Zioptan) 0.0015% one drop daily
- Latanoprostene bunod (Vyzulta)
- Breaks down to Latanoprost and nitric oxide, but with no significant benefit over Latanoprost alone
- Released in 2018, costing 10x the cost of Latanoprost alone (which is $12 per bottle)
- (2018) Presc Lett 25(5): 28
VI. Efficacy: Latanoprost
- Highly effective, low side effect agent
- Currently most prescribed Glaucoma agent worldwide
- References
VII. Adverse Effects
VIII. References
Images: Related links to external sites (from Bing)
Related Studies
latanoprost (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
LATANOPROST 0.005% EYE DROPS | Generic | $1.75 per ml |
xalatan (on 8/17/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
XALATAN 0.005% EYE DROPS | Generic | $1.75 per ml |
bimatoprost (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
BIMATOPROST 0.03% EYE DROPS | Generic | $31.11 per ml |
BIMATOPROST 0.03% EYELASH SOLN | Generic | $26.03 per ml |
lumigan (on 1/14/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
LUMIGAN 0.01% EYE DROPS | $87.53 per ml | |
travoprost (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
TRAVOPROST 0.004% EYE DROP | Generic | $26.10 per ml |
travatan (on 7/27/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
TRAVATAN Z 0.004% EYE DROP | Generic | $22.25 per ml |
tafluprost (on 2/22/2023 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
TAFLUPROST 0.0015% EYE DROP | Generic | $4.29 each |
zioptan (on 10/19/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
ZIOPTAN 0.0015% EYE DROP | Generic | $4.78 each |
ZIOPTAN 0.0015% EYE DROPS | $7.39 each | |
vyzulta (on 1/1/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
VYZULTA 0.024% OPHTH SOLUTION | $87.46 per ml |
Ontology: latanoprost (C0090306)
Definition (NCI) | A prostaglandin F2alpha analogue and a prostanoid selective FP receptor agonist with an ocular hypertensive effect. Latanoprost increases uveoscleral outflow and thereby reduces intraocular pressure. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C072042 |
SnomedCT | 330728002, 108838001, 386926002 |
English | latanoprost, Latanoprost [eye], latanoprost (ophthalmic) (medication), latanoprost (ophthalmic), latanoprost ophthalmic, latanoprost [Chemical/Ingredient], Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate, LATANOPROST, Latanoprost Ophthalmic, Latanoprost [eye] (product), Latanoprost, Latanoprost (product), Latanoprost (substance), Latanoprost [eye] (substance) |
Spanish | latanoprost (ocular) (producto), latanoprost (ocular), latanoprost (producto), latanoprost (sustancia), latanoprost |
Ontology: Xalatan (C0593887)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C072042 |
LNC | LA14718-3 |
English | Pfizer brand of latanoprost, xalatan, Xalatan®, Xalatan |
Ontology: UNOPROSTONE (C0772319)
Concepts | Pharmacologic Substance (T121) , Hormone (T125) , Eicosanoid (T111) |
English | unoprostone, UNOPROSTONE, Unoprostone |
Ontology: travoprost (C0937916)
Definition (NCI) | A synthetic lipophilic isopropyl ester prodrug of the active compound travoprost free acid, a prostaglandin F2alpha analog with anti-glaucoma property. Upon administration, travoprost is hydrolysed to a free acid by corneal esterases, and then selectively stimulating the prostaglandin F (FP prostanoid) receptor, thereby increasing the uveoscleral outflow which leads to a reduction in intra-ocular pressure. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C438103 |
SnomedCT | 391664000, 129493000 |
English | TRAVOPROST @ @ UNIDENTIFIED, TRAVOPROST UNIDENTIFIED, 5-Heptenoic Acid, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-, 1-methylethyl Ester,(5Z)-, travoprost (ophthalmic) (medication), travoprost (ophthalmic), travoprost [Chemical/Ingredient], TRAVOPROST, travoprost, travoprost ophthalmic, Travoprost (product), Travoprost (substance), Travoprost |
Spanish | travoprost (producto), travoprost (sustancia), travoprost |
Ontology: bimatoprost (C0937917)
Definition (NCI_NCI-GLOSS) | A drug used under the name Latisse to increase the length, thickness, and darkness of eyelashes. It is being studied as a way to increase the growth of eyelashes and eyebrows in patients given chemotherapy for cancer. Bimatoprost is also used under the name Lumigan to treat glaucoma (a build-up of fluid in the eye). It lowers pressure in the eye by increasing the flow of natural eye fluids out of the eye. It is a type of prostaglandin analog. |
Definition (NCI) | A synthetic prostamide and structural prostaglandin analogue with ocular hypotensive activity. Bimatoprost mimics the effects of the endogenous prostamides and reduces intraocular pressure by increasing outflow of aqueous humor through both the pressure-sensitive outflow pathway (the trabecular meshwork), and the pressure-insensitive outflow pathway (the uveoscleral routes). It is not clear whether bimatoprost lowers intraocular pressure by stimulating F-Prostanoid receptors or by acting on specific prostamide receptors. |
Concepts | Eicosanoid (T111) , Pharmacologic Substance (T121) |
MSH | C420823 |
SnomedCT | 129492005, 395300006 |
English | BIMATOPROST @ @ UNIDENTIFIED, BIMATOPROST UNIDENTIFIED, 5-Heptenamide, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-,(5Z)-, 5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydrdoxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-(1alpha(Z),2beta(1E,3S*),3alpha,5alpha))-, bimatoprost (medication), bimatoprost [Chemical/Ingredient], bimatoprost, Bimatoprost, Bimatoprost (product), Bimatoprost (substance), BIMATOPROST |
Spanish | bimatoprost (producto), bimatoprost (sustancia), bimatoprost |
Ontology: Lumigan (C0939372)
Concepts | Eicosanoid (T111) , Pharmacologic Substance (T121) |
MSH | C420823 |
English | Lumigan, lumigan, Pharm-Allergan brand of bimatoprost, Allergan brand of bimatoprost |
Ontology: Eescula (C0939466)
Concepts | Pharmacologic Substance (T121) , Eicosanoid (T111) |
MSH | C072630 |
English | Eescula, rescula, Rescula, Ciba Vision brand of isopropyl unoprostone, Novartis brand of isopropyl unoprostone |
Ontology: Travatan (C0939506)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C438103 |
English | Travatan, travatan, Alcon brand of travoprost |
Ontology: Prostaglandin analog antiglaucoma preparation (C1689940)
Concepts | Eicosanoid (T111) , Pharmacologic Substance (T121) |
SnomedCT | 419886007 |
English | Prostaglandin analog antiglaucoma preparation, Prostaglanding analogue anti glaucoma preparation, Prostaglanding analog anti glaucoma preparation (product), Prostaglandin analog antiglaucoma preparation (product), Prostaglandin analogue antiglaucoma preparation, Prostaglanding analog anti glaucoma preparation |
Spanish | preparación contra el glaucoma con análogo de prostaglandina (producto), preparación contra el glaucoma con análogo de prostaglandina, preparación contra el glaucoma con analógo de prostaglandina (producto), preparación contra el glaucoma con analógo de prostaglandina |